An alignment-free strategy for circulating tumor DNA detection and tumor fraction estimation from whole-genome sequencing data.
Blood tests detecting tumor DNA fragments identify recurrence nearly a year before standard imaging in most colorectal cancer patients.
ctDNAmer uses k-mers unique to tumor DNA extracted directly from unaligned sequencing reads to simultaneously detect all variant types in a unified framework, bypassing alignment-dependent bioinformatic confounders. Validation in 90 stage III CRC patients demonstrated recurrence detection ~8 months before radiological imaging in 77% of relapsing patients, and tumor fraction estimates correlated strongly with independent allele-frequency methods.
What the study was
- Study design
- Methodological Development and Validation Study
- Population
- 90 stage III colorectal cancer patients with postoperative plasma cfDNA WGS (3-year follow-up)
- Sample size
- 90
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- PLOS Computational Biology
Why it surfaced
Novel alignment-free ctDNA detection method with validated 8-month recurrence lead time; addresses technical limitations of reference-alignment-dependent approaches.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.